AOD-9604

Could a synthetic peptide provide insights into fat metabolism? AOD-9604, an advanced obesity drug, is a modified fragment of human growth hormone under investigation for its role in lipolysis and fat loss. Preclinical studies suggest intriguing possibilities for metabolic health, yet it's currently restricted to research purposes only.

II. What is this compound?

AOD-9604, often referred to as the Advanced Obesity Drug 9604, is a synthetic 15-amino-acid peptide derived from human growth hormone. It specifically consists of the sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe. Research indicates potential for fat metabolism regulation through its unique structural characteristics.

III. How it works

Research suggests that AOD-9604 may stimulate lipolysis via the beta-3-adrenergic receptor pathway, a critical pathway for breaking down fat [1] PMID: 11739441 . Additionally, studies indicate it can inhibit lipogenesis without significantly affecting blood glucose levels or IGF-1, suggesting a focused approach in metabolic regulation [2] PMID: 11739441 .

• Stimulation of lipolysis via beta-3-adrenergic receptor pathway
  PMID 11739441
• Inhibition of lipogenesis without affecting blood glucose or IGF-1
  PMID 11739441

IV. Research Findings

Preliminary findings suggest that AOD-9604 has the potential for fat loss in preclinical settings, indicating a promising direction for obesity management [3] PMID: 11739441 . Moreover, early research points to potential benefits for metabolic health, although further studies are necessary to establish definitive effects [4] PMID: 11739441 .

• fat-loss preclinical
  PMID 11739441
• metabolic-health preclinical
  PMID 11739441

V. Dosage Context Explained

In animal studies focused on obesity, dosages of AOD-9604 typically range from 300 to 600 mcg per day [5] PMID: 11739441 . These findings provide valuable context for future research protocols, highlighting the need for careful measurement as the field evolves.

• Administration Routes

  subcutaneous

  Range

  300–600 mcg/day

  animal obesity models and anecdotal research protocols

  PMID 11739441

VI. Side Effects: Research Context

Anecdotal evidence suggests that some individuals may experience transient headaches or redness at injection sites. While these side effects appear to be minor, ongoing safety assessments are critical as research progresses.

• transient headache (anecdotal)
• injection site redness (anecdotal)

VII. Frequently Asked Questions